Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Kendle Acquires DecisionLine | Contract Pharma

What are you searching for?

Sign in
Breaking News

Kendle Acquires DecisionLine

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Kendle has acquired DecisionLine Clinical Research Corp., a privately held, early phase CRO with a state-of-the-art medical facility in Toronto, Canada. DecisionLine specializes in Phase I studies involving the measurement of pharmacodynamic effects of central nervous system (CNS) drugs. The company adds scientific expertise with psychopharmacology exploratory/translational medicine capabilities as well as drug development consulting, medical writing, data management, biostatistics and other support services. The acquired business will report into Philip J.W. Davies, vice president, early phase, Kendle. Terms of the transaction were not disclosed.
   
“With Phase I growth expected to outpace the broader outsourcing market at approximately 15% annually, early phase development remains an important need for our customers and an area of significant growth opportunity for Kendle,” said president Simon Higginbotham. “The addition of DecisionLine is an important step in building Kendle’s global capabilities for exploration of early phase drug candidates and supports our strategic initiative to drive growth in our Phase I business.”
   
DecisionLine was founded in 1997 by president and chief executive officer, Edward M. Sellers, M.D., Ph.D., FRCPC, FACP and senior vice president, research development and medical affairs, Myroslava K. Romach, MSc, M.D., FRCPC. The 36,000-sq.–ft. facility has 82 beds and is staffed by a team of approximately 110 full-time and 130 part-time associates. Dr. Sellers will serve as general manager, early phase, Toronto and senior scientist, Kendle International and Dr. Romach will serve as head of clinical operations and medical affairs, early phase, Toronto and senior scientist, Kendle International.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics